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Duramycin, through binding with phosphatidylethanolamine (PE), has been shown to be a selective 
molecular probe for the targeting and imaging of cancer cells. Photodynamic therapy aims to bring 
about specific cytotoxic damage to tumours through delivery of a photosensitising agent and light 
irradiation. Conjugation to biological molecules that specifically target cancer has been shown to 
increase photosensitiser (PS) selectivity and decrease damage to surrounding normal tissue. The aim 
of this study was to target tumour cells with a PE-specific PS therefore duramycin was conjugated to 
a porphyrin based PS which was achieved via direct reaction with the ε-amino group on the lysine 
residue near duramycin's N-terminal. The compound was subsequently purified using RP-HPLC and 
confirmed using mass spectrometry. Binding of the conjugate to ovarian and pancreatic cancer cell 
lines was assessed by flow cytometry. Light irradiation with a light fluence of 7.5 J/cm2 was delivered 
to conjugate treated cancer cells and cell proliferation analysed by MTT assay. The conjugate detected 
PE on all 4 cancer cell lines in a concentration dependent manner and conjugate plus irradiation 
effectively reduced cell proliferation at concentrations ≥0.5 μM, dependent on cancer cell line. 
Reduction in cell proliferation by the irradiated conjugate was enhanced over unconjugated 
duramycin in A2780, AsPC-1 and SK-OV-3 (p b 0.05). In this study we have shown that a duramycin-
porphyrin conjugate retained good binding affinity for its target and, following irradiation, reduced 
cell proliferation of pancreatic and ovarian cancer cell lines. 
 
1. Introduction 
 
Duramycin is a small tetracyclic peptide produced by the bacterium Streptoverticillium cinnamoneus  
[1]. Only 19 amino acids in length duramycin is one of very few identified, relatively, short peptides 
to have a defined 3-dimensional structure  [2]. This structure is stable due to the presence of 3 
thioether bridges formed via the unusual amino acids lanthionine and methyllanthionine. Further a 
covalent linkage be-tween the cysteine at duramycin's N-terminal and an alanine residue produces 
lysinoalanine  [3]. The strength of duramycin's structure is likely to confer its resistance to thermal 
and proteolytic degradation  [2]. The presence of the covalent linkages also results in duramycin's 
stable binding site which selectively recognises the membrane phos-pholipid 
phosphatidylethanolamine (PE) through binding to its polar head group  [4]. Duramycin binds to PE 
with high specificity with a binding molar ratio of 1:1 and a dissociation constant in the low nanomolar 
range  [5]. The lantibiotic cinnamycin, which is structurally similar to duramycin, was shown to induce 
non-specific transbilayer membrane movement of phospholipids in model and cell membranes  [6]. 
It is therefore possible that duramycin self-promotes its own binding to cells by inducing movement 
of PE molecules from the inner to the outer membrane. PE is an abundant membrane phospholipid 
which is ubiquitous in eukaryotic cells. In quiescent cells PE is predominantly located on the inner cell 
membrane along with phosphatidylserine  [7,8]. The asymmetrical distribution of PE and 
phosphatidylserine is enzymatically maintained by a number of ATP-dependent aminophospholipid 
translocases and floppases and ATP-independent scramblases  [9,10]. On activation PE can become 
exposed on the outer cell membrane during a number of physiologically important processes such as 
apoptotic and necrotic cell death, reorganisation of the membrane during cytokinesis and initiation 
of the coagulation cascade  [11–14]. Upregulation of cell surface PE expression has been observed in 
cancer cells, cancer de-rived microparticles and on the tumour endothelium of a variety of in vitro 
and in vivo tumours  [1,15–17]. It is well documented that upregulation of cell surface exposure of 
phosphatidylserine occurs after chemotherapy treatment and that this can increase the procoagulant 
activity of the tumour  [18–20]. On the premise that PE and phosphatidylserine are regulated by the 
same mechanisms and that both are exposed during apoptosis  [21] and after irradiation  [1] a 
number of studies investigated whether PE exposure was upregulated after chemotherapy. It was 
demonstrated that externalisation of PE, detected by duramycin, could potentially be a marker of 
early apoptosis and could be utilised as a detection method for the response to chemotherapy 
treatment  [22–24]. 
 
Photodynamic therapy (PDT) is a minimally invasive treatment that can deliver selective cytotoxic 
activity towards cancer  [25]. PDT requires three essential components; a photosensitising agent, 
light and oxygen. Accumulation of the photosensitiser (PS) at the site of cancer and activation with 
light at a specific wavelength causes the PS to transfer energy, via its excited triplet state, to 
molecular oxygen which is converted from its ground triplet state to an excited singlet state. This 
leads to the generation of cell damaging reactive oxygen species (ROS) which ultimately causes 
apoptotic or necrotic cell death  [25,26]. As well as its direct cytotoxic effect on cancer, PDT can have 
anti-tumour effects via induction of the inflammatory response and damage to tumour vasculature  
[27,28]. PDT has been approved for treatment of a variety of cancer types including premalignant 
and malignant skin cancers  [29,30], early carcinomas of the oral cavity, pharynx, and larynx  [31], 
cancers of the GI tract  [32], prostate cancer, bladder cancer, non-small cell lung cancer and brain 
tumours  [25]. PDT has been used as a synergistic method combined with other major therapies e.g. 
chemotherapy, radiotherapy and surgery  [33–35] as it does not compromise the effect of the 
therapies and therefore can be used in conjunction without effecting future treatment options for 
residual or recurrent malignancy  [25]. A number of PS have been approved for use in clinical oncology 
including m-THCP (meta-tetrahydroxyphenylchlorin, Foscan®), ALA (5-aminolevulinic acid, Levulan®) 
and its methyl ester (Metvix®) and porfimer sodium (Photofrin®). There are a wide range of PS still in 
pre-clinical and clinical trials  [36,37]. 
 
Porphyrins are highly conjugated heterocyclic tetrapyrroles that were first identified as having 
photodynamic properties in the 1970s  [38,39]. A porphyrin PS (5-[Aminobutyl-N-
oxycarbonyl)phenyl]phenyl]-10,15,20-tris(N-methyl-4-pyridinium) porphyrin trichloride) plus light 
irradiation was able to reduce cell survival and prevent colony forming in prostate epithelial cells at 
concentrations of N8.75 μM  [40]. The porphyrins TTP (5,10,15,20-tetra-p-tolyl porphyrin) and THNP 
(5,10,15,20-tetra-p-naphthyl-porphyrin) after a light irradiation dose of 4.5 J/cm2 were able to cause 
cell death in a human melanoma cell line in a concentration dependent manner  [37]. The main 
disadvantage of PDT is the low selectivity of PS to their target, which can lead to damage to 
surrounding normal tissue and sustained skin photosensitivity  [25]. In an attempt to overcome this 
research in PDT in oncology has focused on developing PS's conjugated to tumour targeted biological 
molecules  [28]. Porphyrins have been successfully conjugated to a vari-ety of biomolecules including 
mAbs  [26,41,42], lipoproteins  [43,44] and nanoparticles  [45] which allowed for more targeted 
delivery of PS, and therefore a more specific tissue response with limited damage to nor-mal tissue. 
A number of porphyrins have been developed that conjugate to biomolecules under mild conditions 
through direct reaction with lysine residues  [26,33,46]. 
The two primary amines, cysteine and lysine, at the N-terminal of duramycin offer potential sites for 
conjugation without interference with duramycin's binding site  [3]. Using this theory a number of 
duramycin conjugates have been developed to take advantage of PE as a possible selective molecular 
probe. Fluorescent duramycin conjugates have been used to successfully target and image the 
lymphoma cancer cell line U937  [4], cancer derived microparticles  [17], prostate tumour 
endothelium in rats  [1] and the endothelium of aortic flow dividers  [47]. Duramycin has been 
radiolabelled with gadolinium  [3] and tech-netium-99 m where it was used to image cell death in a 
rat model of acute myocardial infarction  [47–49]. The radiolabelled duramycin conjugate quickly 
accumulated in the PE expressing myocardium. Fast accumulation of a duramycin-PS conjugate could 
potentially provide an advantage over some of the current PS used in the clinical setting as a short 
drug-light interval could be achieved. Thus patients could receive PDT relatively quickly in the 
outpatient setting and would have a reduced treatment duration. In this proof of concept study we 
conjugated duramycin to a porphyrin based PS and assessed its ability to bind to cancer cells via cell 
surface PE. It has been previously shown that the level of cell surface PE expression, detected by 
duramycin, was in-creased on the pancreatic cancer cell lines AsPC-1 and CFPAC-1 when apoptotic 
(induced by campothecin treatment) compared to untreated viable cells and was further increased 
when the cells were necrotic (induced by 30% H2O2 treatment)  [15]. As duramycin can bind to 
quiescent, apoptotic and necrotic cancer cells it was theorised that a duramycin conjugate could 
potentially provide targeted treatment of tumours at all stages of progression. We also examined its 
cytotoxic ac-tivity on ovarian and pancreatic cancer cell lines following irradiation with visible light. 
 
2. Materials and Methods 
2.1. Cell Culture 
The cancer cell lines AsPC-1 and MIA PaCa-2 were purchased from the American Type Culture 
Collection (UK). The cancer cell lines A2780 and SK-OV-3 were purchased from the European 
Collection of Cell Cultures (UK). All cells were grown using distributors' instructions. All cells were 
cultured in either IMDM, McCoy's 5a Medium Modified or RPMI (Lonza, UK) substituted with 10% 
FBS (15% for McCoy's 5a Medi-um Modified) (Bio-Sera, UK) and (v/v); 100 units/mL penicillin, 100 
μg/mL streptomycin (P/S) (Lonza, UK). All serum was filtered using a 0.2 μM syringe filter prior to 
addition to media. When not in use all media was stored between 4 and 6 °C. All cells were incubated 
at 37 °C in a 5% CO2 atmosphere. Cells were cultured in tissue culture flasks (Sarstedt, UK) and 
removed via scraping when cells were 70– 90% confluent. 
 
2.2. Conjugation of Porphyrin to Duramycin 
A solution of duramycin (Sigma-Aldrich, UK, 10 mg, 4.97 × 10−3 mmol) in DMSO (2 mL) plus 
trimethylamine was treated with 5-[4-(N-succinimidyloxycarbonyl)phenyl]-10,15,20-tris(4-
methylpyridinium)porphyrin trichloride  [50] (8 mg, 9.94 × 10−3 mmol) and the resulting solution was 
mixed on a rotating shaker at room temperature for 24 h. The crude material was recovered by 
addition of dichloromethane (5 mL) and filtration through paper. The solid was dissolved in 1 mL of 
0.1% aqueous trifluoroacetic acid (TFA) and the 1:1 porphyrin/duramycin conjugate was isolated by 
semi-preparative HPLC and analysed by electron ionising mass spectrometry (ESI-MS) ( Section 2.3). 
Recovery of 4.8 mg of conjugate was achieved equating to 34.4% yield. An unconjugated, “capped” 
porphyrin was used as a control in which the NHS ester group used for conjugation was reacted with 
butylamine to eliminate any non-specific conjugation  [40]. All photosensitiser containing compounds 
were kept, protected from light, at −20 °C. Final concentrations of the re-suspended lyophilised 
powder of the conjugate and “capped” control were determined using UV–visible 
spectrophotometry. 
 
 
Fig. 1. Structure of duramycin-porphyrin conjugate. A covalent amide bond was formed through the reaction 
with the NHS ester of the porphyrin 5-[4-(N-succinimidyloxycarbonyl)phenyl]-10,15,20-tris(4-methylpyridinium) 
porphyrin trichloride and the ε-amino group of the lysine residue at duramycin's N-terminal in the organic 
solvent DMSO 
 
2.3. Analyses and Purification of Duramycin-Porphyrin Conjugate 
RP-HPLC-PDA analyses were performed on an Agilent 1200 HPLC system (Agilent, Germany) equipped 
with a G1312B BinPump SL, G13798 degasser, G1367D HiP ALS SL plus autosampler, a G1316B column 
compartment (set at 35 °C), and a G1315C diode array detector (acquisition rate, 80 Hz; scan rate: 
380–600 nm, step: 1 nm), using a Gemini C18 column, 5 μ, 150 × 4.6 mm, 110 Å column (Phenomenex, 
UK), equipped with a SecurityGuard C18 (ODS) 4 × 3.0 mm ID guard column (Phenomenex, UK). The 
injection volume was 20 μL, and the flow rate was 1 mL/min. Mobile phase consisted of a mixture of 
0.1% TFA in deionised water (18.2 MΩ, Elga Purelab Ultra ULXXXGEM2), sol-vent A, and 0.1% TFA in 
HPLC-grade acetonitrile, solvent B. The gradient for the elution was as follows: 0–2 min, 5% B; 2–7 
min, B to 95%; 7– 12 min, 95% B; 12–12.1 min, B to 5%. Duramycin Rt = 7.32, porphyrin Rt = 7.01, 
conjugate Rt = 6.20 min (See Supplementary Fig. S-1). RP-HPLC purifications were carried out on a 
Jasco HPLC system equipped with a PU-1580 LC pumps, HG-1580 degasser, AS-1555 autosampler and 
MD-1515 array UV–visible detector, using a Luna C18, 5 μ, 250 × 10 mm, 110 Å (Phenomenex, UK), 
at a flow rate of 2.5 mL/min. Mobile phase consisted of a mixture of 0.1% TFA in deionised water 
(18.2 MΩ, Elga Purelab Ultra ULXXXGEM2), solvent A, and 0.1% TFA in HPLC-grade acetonitrile, 
solvent B. The gradient for the elution was as follows: 0–8.5 min, 5% to 51% B; 8.5–13 min, 51% B; 
13–14 min, 51 to 95% B; 14–18 min, 95% B, 18–18.1 min, 95 to 5% B. Conjugate Rt = 6.20 min (See 
supplementary Fig. S-1). Q-TOF-MS data were acquired in positive mode scanning from 400 to 3000 
m/z with and without auto MS/MS fragmentation. Ionisation was achieved with an Agilent JetStream 
electrospray source and infused internal reference masses. Agilent 6540 Q-TOF-MS parameters: gas 
temperature, 325 °C; drying gas, 10 L/min; and sheath gas temperature, 400 °C. ESI-MS (+): 675.66 
[(M + 4H+)/4]4+ (exp: 675.67). Conjugate Rt = 7.34 (see Supplementary Fig. S-2). 
 
2.4. Flow Cytometric Detection of Phosphatidylethanolamine 
Cells (1 × 105) were re-suspended in 25 μL PBS and added to a 5 mL polypropylene tube (Sarstedt, 
UK). Duramycin-porphyrin conjugate (5 μL) at required concentration was added to the tubes and 
incubated at room temperature in the dark for 30 min. Cells were washed with PBS, centrifuged at 
320g for 3 min and re-suspended in 300 μL PBS and then analysed using a BD FACScalibur (BD 
Biosciences, UK). 
 
2.5. Flow Cytometric Analysis of Forward Scatter and Side Scatter 
Analysis of forward scatter (FSC) and side scatter (SSC) data was performed using BD CellQuest Pro 
software™ version 5.1 (BD Biosciences, UK) after cells were processed using the method described 
above. FSC and SSC data using the unconjugated duramycin was collected as part of a study to 
determine the effect of duramycin on cell viability over a 2 hour time course (unpublished data). 
These cells were processed using a flow cytometric cell viability analysis method de-scribed 
previously  [16]. Briefly cells (2 × 105) were incubated with an appropriate concentration of 
unconjugated duramycin at room temperature in the dark for 30 min and analysed using Annexin V: 
FITC Apoptosis Detection Kit I (BD Biosciences, UK). 
 
2.6. Competition Binding Assays 
Cells (2 × 105) were re-suspended in 40 μL PBS and added to a 5 mL polypropylene tube (Sarstedt, 
UK). Duramycin-porphyrin conjugate (10 μL, final concentration 50 μM) was added to the tubes and 
incubated at room temperature in the dark for 5 min. The cells were washed with PBS, centrifuged 
at 320g for 3 min and re-suspended in 40 μL PBS except for the 0 minute tube which was re-
suspended with 300 μL PBS and analysed by flow cytometry. Unconjugated duramycin (10 μL, final 
con-centration 50 μM) was added to the remaining tubes. After appropriate incubation time (2, 5, 15 
or 30 min) 250 μL PBS was added to the tubes and the cells analysed using flow cytometry. 
 
2.7. Photodynamic Light Treatment Cells 
Cells (8 × 105) in serum free medium were added to 5 mL polypro-pylene tubes (Sarstedt, UK) 
containing duramycin-porphyrin conjugate at required concentration (0–10 μM) and incubated in the 
dark at 37 °C in a 5% CO2 atmosphere for 5 min. Cells were then washed with 3 mL medium so as to 
remove any unbound conjugate and centrifuged at 300g for 10 min and re-suspended in 1 mL 
medium. Cells (8 × 104) were then plated into 96 well plates and incubated in the dark at 37 °C in a 
5% CO2 atmosphere for 5 min. The PDT light supply (9 × 14 LED Array, wavelength 620–660 nm) was 
allowed to stabilise and irradiance reading taken using a R203 Macam radiometer (Irradian Ltd. UK). 
After incubation one plate was irradiated with a light fluence of 7.5 J/cm2 red light whilst the other 
served as the dark control (i.e. not irradiated). After light treatment 5 μL FBS was added to each well 
and the plates incubated at 37 °C in a 5% CO2 atmosphere for 24 h. 
 
2.8. Cell Proliferation Assay 
After 24 h incubation 10 μL MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; 
thiazolyl blue) (Sigma-Aldrich, UK) (12 mM solution in PBS) was added to each well of the 96 well 
plates. The plates were incubated at 37 °C in a 5% CO2 atmosphere for 4 h and then the crystals were 
dissolved by adding 150 μL of acid-alcohol mix-ture (0.04 mol/L HCl in absolute 2-propanol). The 
plates were then analysed at 570 nm using a Biotek ELX800 Universal Microplate Reader (Corgenix 
Ltd., UK). Percentage cell survival was expressed relative to control values. 
 
2.9. Statistical Analysis 
Statistical difference between the irradiated and non-irradiated conjugate conditions and between 
the duramycin-porphyrin conjugate and unconjugated duramycin conditions was performed using 
the t-test for unequal variances (heteroscedastic) and a p value of b0.05 was considered statistically 
significant. 
 
3. Results 
 
3.1. Phosphatidylethanolamine Detection 
The duramycin-porphyrin conjugate ( Fig. 1) was able to detect cell surface PE expression on the 
ovarian cancer cell lines, A2780 and SK-OV-3, and the pancreatic cancer cell lines, AsPC-1 and MIA 
PaCa-2 using flow cytometry. Log10 median PE fluorescence (635 nm laser, FL-4 flow cytometer 
channel) was used to express levels of detected PE. The duramycin-porphyrin conjugate detected 
levels of PE in a con-centration dependent manner on all 4 cell lines (n = 2) ( Fig. 2). Optimal PE 
detection was seen using the highest concentration (1 mM) of the conjugate. As an average of all 4 
cell lines the log10 median PE fluorescence increased from 0.17 ± 0.007 (n = 8) when detected with 1 
μM conjugate to 2.21 ± 0.192 (n = 8) when detected with 1 mM conjugate. The duramycin-porphyrin 
conjugate was detectable through the flow cytometer's FL-4 channel (flow cytometer's 635 nm laser) 
due to fluorescence of the porphyrin component of the conjugate at this wavelength. 
  
Fig. 2. Detection of cell surface PE on ovarian and pancreatic cancer cell lines using duramycin-porphyrin 
conjugate. i) Median PE fluorescence (FL-4 flow cytometer channel, 635 nm laser) was used to express detected 
levels of PE (plotted on a logarithmic to base 10 scale). The conjugate was able to detect PE on the cell surface 
of all 4 cancer cell lines, A2780, AsPC-1, MIA PaCa-2 and SK-OV-3, in a concentration dependent manner. Error 
bars show standard deviation of 2 replicates. ii) Flow cytometry histograms showing detectable shift in 
fluorescence on a) A2780, b) AsPC-1, c) MIA PaCa-2 and d) SK-OV-3 cells (purple) using 0.1 μM (green) and 10 
μM (pink) duramycin-porphyrin conjugate. 
 
3.2. Competitive Binding for Phosphatidylethanolamine 
To investigate whether the binding ability of the duramycin-porphyrin conjugate to PE was affected 
by the conjugation procedure a competition assay was performed using flow cytometry. The 
unconjugated duramycin was unable to compete for cell surface PE on the cancer cell lines which had 
been pre-incubated with duramycin-porphyrin conjugate ( Fig. 3). The median PE fluorescence (FL-4 
channel) of A2780 and MIA PaCa-2 was determined, using the pre-bound conjugate, as 10.9 ± 0.75 
(n = 2) and 16.7 ± 5.9 (n = 2), respectively. Duramycin was incubated with the cancer cell lines for 0, 
2, 5, 15 and 30 min to allow time to potentially displace the conjugate and competitively bind to PE. 
The median PE fluorescence of MIA PaCa-2 remained con-stant, within standard deviation, at each 
interval across the 30 minute time course. The median PE fluorescence of the A2780 however in-
creased over time to the maximum of 12.8 ± 0.16 (n = 2) at 30 min. The unaffected binding affinity of 
the conjugate for PE after ligation to porphyrin provides evidence that the conjugation method used 
in this study does not disrupt PE binding. Alternatively, the assay was per-formed with the 
unconjugated duramycin pre-bound and the conjugate as the competing species, similarly over a 30 
min time course. The median PE fluorescence (FL-1 channel) detected remained constant at 8.3 ± 1.8 
(n = 2) for A2780 and 11.7 ± 1.4 (n = 2) for MIA PaCa-2 over the 30 min. However it cannot be certain 
that the FL-1 signal originated from the unconjugated duramycin (labelled with a tertiary FITC 
antibody detected at 488 nm) as the duramycin-porphyrin conjugate signal is also detectable on this 
channel. 
 
Fig. 3. Competitive binding for PE between pre-bound duramycin-porphyrin conjugate and unconjugated 
duramycin. The unconjugated duramycin was unable to compete against the conjugate for cell surface PE on 
the cancer cell lines A2780 and MIA PaCa-2. The median PE fluorescence of MIA PaCa-2 remained constant, 
within standard deviation, at each interval across the 30 minute time course. However the median PE 
fluorescence of A2780 increased slightly over time. Error bars show standard deviation of 2 replicates. 
 
3.3. Effect on Cell Size and Morphology 
We have previously reported the effect that unconjugated duramycin has on the morphology of 
A2780, AsPC-1, MIA PaCa-2 and SK-OV-3 with relation to an increase in cell size (FSC) and internal cell 
complexity/granularity (SSC)  [16]. FSC and SSC data collected via flow cytometry was analysed after 
the same 4 cancer cell lines were treated with the duramycin-porphyrin conjugate at concentrations 
between 1 μM and 1 mM ( Fig. 4). A2780 and SK-OV-3 increased in SSC when treated with 1 mM 
conjugate and AsPC-1 and MIA PaCa-2 increased in SSC when treated with N250 μM (n = 2). A2780 
and MIA PaCa-2 showed a slight increase in FSC when treated with 1 mM duramycin-porphyrin 
conjugate (n = 2). 
 
Fig. 4. The effect of duramycin-porphyrin conjugate on the forward scatter and side scatter properties of 
ovarian and pancreatic cancer cell lines. The effect on FSC of a) unconjugated duramycin and b) duramycin-
porphyrin conjugate and the effect on SSC of c) unconjugated duramycin and d) duramycin-porphyrin conjugate. 
Unconjugated duramycin has the ability to increase FSC (cell size) of AsPC-1 and SK-OV-3 cells at N50 μM and 
increase SSC (cell granularity) of A2780, AsPC-1, MIA PaCa-2 and SK-OV-3 at N200 μM. Duramycin-porphyrin 
conjugate slightly increased FSC of A2780 and MIA PaCa-2 at 1 mM. SSC was increased in A2780 and SK-OV-3 
when treated with 1 mM conjugate and AsPC-1 and MIA PaCa-2 when treated with N250 μM conjugate. Error 
bars show standard deviation of 2 replicates 
 
3.4. Photodynamic Cytotoxicity Assays 
The duramycin-porphyrin conjugate was used in the photodynamic treatment of the cancer cell lines 
A2780, AsPC-1, MIA PaCa-2 and SK-OV-3. Each concentration of either “capped” control porphyrin, 
unconjugated duramycin or duramycin-porphyrin conjugate was repeated 4 times as biological 
replicates and each assay performed 3 times as tech-nical replicates. The irradiated duramycin-
porphyrin conjugate was able to reduce the cell survival of the A2780 cancer cells at concentrations 
≥5 μM ( Fig. 5a). A significant difference (p = 0.029) in reduction in cell survival between the irradiated 
and non-irradiated conjugate treated cells occurred at 5 μM where cell survival was 17.7 ± 26.9% and 
65.9 ± 2.4%, respectively. The conjugate at the highest concentration of 10 μM was able to reduce 
cell survival to 3.2 ± 3.7%. The unconjugated duramycin caused a slight reduction in cell survival at 
concentrations N5 μM. The non-irradiated “capped” control porphyrin (porphyrin with no duramycin) 
showed no cytotoxicity. The irradiated “capped” control porphyrin however showed similar levels of 
cytotoxic-ity as the irradiated conjugate treated cells at concentrations N5 μM. MIA PaCa-2 cells 
showed similar sensitivity to photodynamic light treatment as A2780. For conjugate treated MIA 
PaCa-2 cells the differ-ence in reduction of cell survival between the irradiated and non-irradi-ated 
conditions also occurred at 5 μM ( Fig. 5b) though this was not significantly different (p = 0.32). At 10 
μM cell survival was reduced to 36.3 ± 13.4%. At a concentration of 10 μM the cell survival for the ir-
radiated and non-irradiated unconjugated duramycin was 40.3 ± 16.3% and 43.5 ± 14%, respectively. 
The non-irradiated conjugate and “capped” control porphyrin showed no cytotoxicity. The irradiated 
“capped” control porphyrin reduced cell survival slightly at the highest concentration of 10 μM. The 
cancer cell lines AsPC-1 ( Fig. 5c) and SK-OV-3 ( Fig. 5d) were more sensitive to photodynamic light 
treatment than A2780 and MIA PaCa-2. The significant reduction in cell survival between the 
irradiated and non-irradiated conjugate occurred at 2.5 μM (p = 0.018) for AsPC-1. The cell survival 
of non-irradiated AsPC-1 cells treated with 2.5 μM conjugate was 86.4 ± 4.9% compared to irradiated 
cells at 6.3 ± 2.4%. For SK-OV-3 cells the significant reduction in cell survival occurred at 0.5 μM (p = 
0.039) and was 95.5 ± 3.9% and 86.9 ± 3.8% for the non-irradiated and irradiated conditions, 
respectively. This reduction in cell survival became more pronounced at 2.5 μM where cell survival 
for non-irradiated conjugate treated cells was 91.2 ± 7.7% and only 11.7 ± 4.4% for irradiated cells. 
At the highest concentration of 10 μM duramycin-porphyrin conjugate reduced cell survival to 1.83 
± 1% in AsPC-1 and 2.76 ± 2.2% in SK-OV-3. The non-ir-radiated conjugate showed dark toxicity at 
concentrations N5 μM and he irradiated “capped” control porphyrin control slightly reduced cell 
survival at 10 μM for both cancer cell lines. Unconjugated duramycin showed a cytotoxic effect in a 
concentration dependent manner for both AsPC-1 and SK-OV-3. For example at 10 μM the irradiated 
unconjugated duramycin reduced cell survival to 48.7 ± 20.2% in AsPC-1 and 60.6 ± 7.2% in SK-OV-3. 
Indeed unconjugated duramycin reduced cell survival in a concentration dependent manner in all 4 
cell lines. However this is to be expected due to the cytotoxic abilities of unconjugated duramycin at 
these concentrations as seen previously  [16]. Yet, a significantly enhanced cytotoxic effect of the 
irradiated duramycin-porphyrin conjugate over unconjugated duramycin occurred at concentrations 
N1.25 μM for A2780 (p = 0.045) and AsPC-1 (p = 0.03) and at all concentrations (0.5–10 μM) for SK-
OV-3 (p = 0.046). Reduction in cell survival of MIA PaCa-2 cells when treated with irradiation plus 
conjugate was not significantly different to the un-conjugated duramycin treated cells (p = 0.91). 
 
Fig. 5. PDT Treatment of ovarian and pancreatic cancer cell lines. The irradiated duramycin-porphyrin 
conjugate at concentrations ≥0.5 μM significantly reduced cell survival of AsPC-1, A2780 and SK-OV-3 cells 
when compared to the non-irradiated conjugate. a) The unconjugated duramycin caused a slight reduction in 
cell survival of A2780 cells at concentrations N5 μM. The irradiated capped porphyrin treated cells showed 
similar levels of cytotoxicity as the irradiated conjugate treated cells at concentrations N5 μM. b) The 
irradiated capped porphyrin reduced cell survival of MIA PaCa-2 cells slightly at the highest concentration of 
10 μM. Reduction in cell survival in conjugate treated cells was not significantly different to unconjugated 
duramycin treated cells and there was no significant difference between irradiated and non-irradiated 
conjugate conditions. c) and d) Both AsPC-1 and SK-OV-3 showed dark toxicity at concentrations with non-
irradiated conjugate N5 μM. The irradiated capped porphyrin control slightly reduced cell survival at 10 μM. 
Unconjugated duramycin showed cytotoxic effect in a concentration dependent manner. Error bars show 
standard deviation of 3 independent experiments with 4 repetitions each.
 
4. Discussion 
Conjugation of tetrapyrroles to peptides can be chemically challenging due to the requirement 
of bringing the two moieties together regioselectively whilst maintaining their separate 
functionalities  [33]. 
In this study conjugation occurred by the formation of a covalent amide bond between an N-
hydroxysuccinimide (NHS) ester of the porphyrin and the ε-amino group on the lysine residue 
at duramycin's N-terminal. The reaction conditions were chosen in order to target the desired 
lysine residue. NHS esters are highly amine-reactive and form stable amide bonds primarily 
with lysine's ε-amino group and the α-amino group of the N-terminal residue under 
physiological or slightly alkaline pH (pH 7.2–9)  [51]. As the NHS ester was non-sulphonated, 
causing it to be water insoluble, the reaction was performed in the water miscible organic 
solvent DMSO. To produce a pH of pH 9, provide a base in the non-aqueous DMSO solution 
and catalyse the reaction be-tween NHS and lysine trimethylamine (TEA) was added  [50]. In 
addition to the reaction conditions used the structure of duramycin means it is reasonable to 
presume the desired location for conjugation was achieved. The only exposed reactive 
functionality on duramycin is the ε-amino group of the N-terminal lysine residue as the α-
amino group of the lysine and the amino terminus itself is folded inside the peptide's structure. 
The conjugation of the porphyrin to duramycin at this chosen location should minimise 
interference with the PE binding site  [3]. A number of biological molecules conjugated to 
porphyrin through lysine residues have been shown to retain their antimicrobial function  
[50,52,  53]. The scFv antibody fragment LAG-3 when conjugated through its ly-sine residues 
to a porphyrin PS was shown to bind to the colorectal cancer cell line Caco-2 and effectively 
induce cell death following 15 J/cm2 light treatment  [26]. 
 
In this study the duramycin-porphyrin conjugate was used to detect cell surface PE expression 
on the 4 cancer cell lines A2780, AsPC-1, MIA PaCa-2 and SK-OV-3 via flow cytometry. In this 
way the conjugate was tested to see whether the duramycin component's ability to bind the 
ethanolamine head group of PE had been altered during conjugation. It was also assessed 
herein whether the porphyrin had retained its fluorescent properties. The conjugate detected 
PE expression on all 4 cell  
lines and was detected in a concentration dependent manner thus verifying the conjugates 
ability to bind its target and maintain detectable fluorescence. Though it was not shown 
directly in this study that there was an upregulation of PE on the cancer cell lines compared to 
their nor-mal counterparts, we have previously shown that PE expression occurs on a broad 
range of cancer cell lines  [16]. Also it has been recently shown that PE was present in much 
higher abundance in xenografts formed from a number of different tumour types (lung, colon, 
pancreatic and glioblastoma) than in their normal tissue counterparts  [54]. It is well 
established that duramycin binds to PE when exposed on the sur-face of cells and on the 
luminal surface of the endothelium  [1,15,47,  49,55]. Duramycin was used in conjunction with 
bavituximab to image the co-localisation of exposed PE and phosphatidylserine on irradiated 
endothelial cells  [56]. The cells were stained 24 hour post irradiation and coincidental 
exposure of the two phospholipids was observed on the surface of the cells. Duramycin 
staining occurred only where PE was exposed on the surface of the cell, even when the 
exposure area moved due to cell movement across the dish, and this staining was maintained 
on the surface over the 8 hour imaging period. Therefore we theorise that the binding of 
duramycin and thus the duramycin-porphyrin conjugate occurs only at the cell surface where 
PE is exposed and is likely not internalised. To further investigate whether the conjugate's PE 
binding ability was affected by the conjugation procedure a competition assay was performed 
via flow cytometry. Unconjugated duramycin did not have the ability to outcompete the 
conjugate for binding of cell surface PE. The median PE fluorescence detected remained 
constant for MIA PaCa-2 cells over the 30 minute time course and was seen to slightly increase 
for A2780. 
 
We have previously reported that unconjugated duramycin has an effect on the FSC and SSC 
properties of cancer cell lines  [16]. Duramycin has the ability to increase cell size (FSC) of AsPC-
1 and SK-OV-3 cells at N50 μM and increase cell granularity (SSC) of A2780, AsPC-1, MIA PaCa-
2 and SK-OV-3 at N200 μM. Necrotic cell death is associated with swelling of the cell followed 
by rapid release of intracellular content and an increase in granularity which have been linked 
to an increase in FSC and SSC, respectively  [57]. An increase in SSC was seen to correlate with 
increased granularity in prostate cancer cells (LNCaP and PC3)  [58]. Cells with an increased 
SSC in the renal proximal tubular epithelial cell line LLC-PK1 were identified as apoptotic by 
flow cytometry and those with an increased FSC as necrotic  [59]. Heightened SSC was also 
seen in early apoptotic cells where condensation of the cell nucleus and cytoplasm during cell 
shrinkage lead to enhanced light refraction  [60]. However it is important to state that 
morphological and cell size changes measured via light scatter should be considered as 
supportive rather than as definitive evidence of cell death. We have previously shown via 
confocal imaging that duramycin treated AsPC-1 cells lose cell membrane staining 
accompanied with an uptake of propidium iodide suggesting a loss in membrane integrity or 
cell death. An increase in cell size was also observed, which is indicative of cell swelling prior 
to cell death  [16]. The duramycin-porphyrin conjugate also effected the FSC/SSC properties of 
the ovarian and pancreatic cancer cell lines. FSC was increased in A2780 and MIA PaCa-2 when 
treated with 1 mM conjugate and SSC increased in all 4 cell lines though AsPC-1 and MIA PaCa-
2 at N250 μM and A2780 and SK-OV-3 at 1 mM. The similar effects on FSC and SSC produced 
by duramycin and duramycin-porphyrin conjugate could provide additional evidence of 
duramycin's maintained functionality when conjugated to porphyrin. The higher concentration 
of conjugate required to exert this effect on the cell lines compared to duramycin alone is 
beneficial to PDT where minimal non-specific dam-age is a desired characteristic of any PS  [36]. 
 
A number of studies in the literature have investigated the effect of PDT on ovarian and 
pancreatic cancer in a variety of models including cell lines  [61], 3D cell culture  [62–64], 
transplanted mice  [65,66] and Phase I/II human trials  [67,68]. A benzoporphyrin derivative 
(BPD) at 0.25 μM was able to reduce cell viability and volume in the human ovarian carcinoma 
cell line OVCAR5 and penetrate well through OVCAR5 3D cell culture  [62,63]. In another study 
in which OVCAR5 cells were grown in a culture film a fibre optic delivery system was used 
where the PS (pheophorbide) and oxygen gas was delivered separately  [64]. Good diffusion of 
the PS to cells beyond the reach of the probe tip was observed. Balb/C mice transplanted with 
the ovarian cancer cell line OVCAR3 where treated with an immunoconjugated PS and 
irradiated with in vivo results showing targeted treatment and minimal damage to the 
surrounding vasculature  [65]. A pancreatic cell line panel showed the cancer cell line AsPC-1 
was particularly sensitive to PDT. Treatment of this cell line with verteporfin at 250 nM with a 
light dose of 10 J/cm2 was effective enough to induce complete cell death  [61]. Verteporfin 
has been used successfully in a Phase I/II trial against advanced pancreatic cancer where it 
accumulated quickly in the target tissue, induced necrotic cell death and had a fast clearance 
via excretion in bile  [68]. 
 
In this study we used 2 ovarian and 2 pancreatic cancer cell lines to evaluate the cytotoxic 
extent of our newly developed PS, duramycin-porphyrin conjugate, taking advantage of 
duramycin's specificity for cell surface expressed PE. The duramycin-porphyrin conjugate was 
able to reduce cell survival of all 4 cancer cell lines after irradiation with a light dose of 7.5 
J/cm2 red light. The difference in cell survival be-tween the non-irradiated and irradiated cells 
treated with the conjugate occurred at 0.05 μM for SK-OV-3, 2.5 μM for AsPC-1 and 5 μM for 
A2780 and MIA PaCa-2 (though not statistically significant for MIA PaCa-2). Treatment with 10 
μM conjugate was effective enough to reduce cell survival to b6% in A2780, AsPC-1 and SK-
OV-3. MIA PaCa-2 exhibited less sensitivity to the PDT light treatment as cell survival was only 
ever reduced to 36.3% at the highest concentration. Reduction in cell survival of MIA PaCa-2 
in conjugate treated cells was not significantly different to unconjugated duramycin treated 
cells. The greater resistance to irradiation and the lack of increased cytotoxic effect of the 
conjugate over duramycin alone may suggest that MIA PaCa-2 cancer cells may not be a 
candidate for PDT using this PS. Out of the 2 pancreatic cancer cell lines used in this study MIA 
PaCa-2 is the less aggressive form. Samkoe et al.  [66] discovered that aggressive, fast growing 
pancreatic cancer (AsPC-1) responded better to verteporfin PDT than the less aggressive cell 
line (PANC-1) in transplanted mice. In their vascular occlusion experiments 40 J/cm light dose 
was enough to induce com-plete necrosis in the tumours of AsPC-1 transplanted mice but not 
in PANC-1. They concluded that this difference in reaction to light treament between cell lines 
could depend on tumour aggressiveness and other inherent biophysical properties. It has been 
observed in human trials that these differences in response to light treatment are of clinical 
importance where light dose can raise different reactions even in patients with the same type 
of malignancy  [28,67]. 
 
The “capped” porphyrin control when irradiated reduced cell survival slightly in AsPC-1, SK-
OV-3 and MIA PaCa-2 at 10 μM. In a recent study  [40] this “capped” control porphyrin was 
used in PDT experiments against benign and malignant prostate cells to assess its cytotoxic 
potential. “Capped” porphyrin N8.75 μM was seen to induce necrosis and prevent colony 
forming in irradiated prostate cells. In the A2780 cancer cell line the capped porphyrin control 
produced similar levels of cytotoxicity as to that produced by the irradiated conjugate. An in-
creased uptake and localisation of the “capped” porphyrin could potentially explain this 
increased sensitivity. However DNA damage in the prostate cells (suggesting localisation 
occurred in the nucleus) was induced after 1 hour incubation with the porphyrin  [40]. This 
movement into the cell and localisation of the “capped” control porphyrin is unlike-ly to have 
occurred in the A2780 cells in the relatively short incubation of 5 min used in this study. 
 
The differences in sensitivities to irradiation between cancer cell lines could potentially be 
explained by the cytoprotective mechanisms that cancer cells can employ to escape PDT 
induced cell death. Antioxidant molecules and detoxifying enzymes such as superoxide 
dismutase (SOD) present in cancer cells have been implicated in the protection against PDT 
effects  [25]. Other cytoprotective mechanisms have been demonstrated to be induced by PDT 
itself including the i) initiation of stress-related transcription factors e.g. hypoxia inducible 
factor (HIF) and nuclear factor erythroid 2-related factor 2 (NRF2), ii) increased heat shock 
protein (HSP) levels e.g. elevated HSP60 and HSP70 have been seen to be inversely correlated 
with PDT sensitivity and iii) inhibition of NF-ᴋB which can activate anti-apoptotic genes  [25]. 
The literature reports at least some of these protective mechanisms are active in the ovarian 
and pancreatic cancer cell lines used in this study. An upregulation of HIF-1-α, an important 
factor in tumour metastasis and progression, was seen to accompany the hypoxic state of 
A2780 tumours and has also been observed in hypoxia induced MIA PaCa-2 cells and following 
oxidative stress-induced ROS production in SK-OV-3 cells  [71]. SK-OV-3 cells also have an 
upregulation of the antioxidant gene SOD2  [72] which could protect against harmful PDT 
effects. This ovarian cancer cell line has also been shown to have enhanced NF-ᴋB activity, 
when stimulated by ROS, which lead to the activation of anti-apoptotic genes  [73]. NRF2 is the 
principal transcription factor of many antioxidant and detoxification genes and is 
overexpressed in A2780  [74], SK-OV-3  [75] and AsPC-1 cells  [76,77] and can be induced in the 
presence of ROS especially in pancreatic cancer  [77]. HSPs can bind oxidatively damaged 
proteins and play a role in pro-survival path-ways  [25]. HSP70 is overexpressed in MIA PaCa-2 
cells  [78] and is found in much higher quantities in tissue from patients with ovarian cancer 
than in normal ovarian tissue  [79]. The effectiveness of PDT relies on an available and 
sustained oxygen supply to tissue, which may be reduced in hypoxic conditions  [80]. A2780 
xenografts in a murine model of ovarian cancer were found to be extremely hypoxic (2.0 ± 0.7 
mmHg) when compared to RIF-1 xenografts (7.8 ± 1.4 mmHg); a typical hypoxic tumour model  
[69].  
An important property of any good PS is a high intersystem crossing (ISC) yield i.e. a high 
possibility of conversion from the excited singlet state to the longer lived excited triplet state, 
from which energy transfer to ground state (triplet) oxygen occurs  [28]. Tetrapyrroles, such as 
the porphyrin moiety used in this study, are very efficient at undergoing ISC  [81]. The benefit 
of conjugating tetrapyrroles with peptides is that their small size allows for good tissue 
penetration and usually renders them non-immunogenic  [33]. An advantage of the type of 
porphyrin used in this study is that the conjugation procedure does not produce reactive 
intermediates or by-products  [26,46]. This porphyrin has previously been shown to exhibit 
antibacterial properties, be an efficient cytotoxic after 5 minute irradiation and be stable 
against photodegradation [50]. The duramycin-porphyrin conjugate reported here is an 
effective PS for the targeted PDT treatment of cancer cells. With a relatively low (in vitro) 
cytotoxic concentration of ≥0.5 μM (de-pendent on cell line) the conjugate offers benefits over 
unconjugated duramycin induced cell death. At these low concentrations duramycin does not 
cause necrosis but can reliably bind cell surface expressed PE  
Unconjugated duramycin has been shown to bind PE expressed on the tumour vasculature  [1]. 
Through the possibility of targeted irradiance the duramycin-porphyrin conjugate could allow 
for specific death of the tumour and therefore reduce the risk of collateral damage to 
surrounding normal tissue. Photodynamic effect usually occurs very close to the localisation of 
the PS  [25] and when the PS's binding site is the plasma membrane necrotic cell death can 
very rapidly follow irradiation  [82]. As the duramycin-porphyrin conjugate binds to cancer cell 
membranes it is possible that cell death occurs via rapid necrosis which may reduce the risk of 
PDT-induced cytoprotective mechanisms. 
PDT is evidently an effective anti-cancer therapy though only a limited number of PS have been 
approved by the FDA and EU for use in the clinical setting  [28,37]. For PDT to be better utilised 
as a treatment strategy the development of PS that possess selectivity for binding sites 
overexpressed or enhanced on a wide range of cancer types is needed. In this proof of concept 
study we have shown that the PS duramycin-porphyrin conjugate retained good binding 
affinity for its target and, following irradiation, reduced cell survival of pancreatic and ovarian 
cancer cell lines in a concentration dependent manner. As we have previously shown, 
duramycin has the ability to bind to cell surface expressed PE on a range of cancer cell lines  
[16], and so we hypothesise that this PS could potentially be used against a number of different 
cancer types. Further work with duramycin-porphyrin conjugate in the in vivo environment 
could potentially confirm this conjugate as a promising new PS in the PDT treatment of cancer. 
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